相关实验视频

Updated: May 26, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

石康宁-Cu (II) 超分子聚合物通过缩和缩表现出抗瘤活性

Hongyang Zhang^1,2,3, Rui-Hong Gong^2,4, Yu Shan Lin²

¹College of Pharmacy, Shenzhen Technology University, Shenzhen, 518118, China.

Advanced healthcare materials

|February 24, 2025

概括

这项研究介绍了SHICU,一种超分子聚合物,它释放了Shikonin和铜 (Cu(II)) 以诱导通过缩和缩产生协同作用的抗瘤效应,提供了一种新的癌症治疗方法.

科学领域:

材料科学材料科学材料科学
生物医学工程生物医学工程
癌症研究癌症研究

背景情况:

具有可逆金属结合体键的高分子聚合物可以集成和释放治疗剂.
细胞内药物递送系统对于向癌症治疗至关重要.

研究的目的:

开发一种新型的超分子聚合物,SHICU,用于协同的癌症治疗.
调查SHICU的双重抗瘤机制,包括反应性氧物种 (ROS) 依赖性缩和亡.

主要方法:

使用Shikonin配体和Cu (II) 离子合成超分子聚合物SHICU.
研究由细胞内谷氨 (GSH) 触发的SHICU解离.
在瘤细胞中评估释放的Shikonin和Cu (II) 的协同抗瘤作用,以及SHICU聚合物本身.

主要成果:

在GSH降解时,SHICU会分离,释放出Shikonin,Cu(II) 和聚合物碎片.
释放的西康宁和Cu (II) 通过ROS依赖性缩诱导协同作用的抗瘤作用.
完整的SHICU触发了瘤细胞中的cuproptosis,一种独特的细胞死亡途径.

结论:

SHICU通过结合ROS依赖性缩和cuproptosis显示了双重抗瘤功能.
这种高分子聚合物为开发创新的癌症疗法提供了一个有前途的战略.
超分子聚合物与cuproptosis的整合为药物开发开辟了新的途径.

关键词:

这是一种抗瘤药物.这种疾病叫做cuproptosis.尸体消亡 (necrosis) 是一种致死症.石康宁- (II) 复合体这是一种超分子聚合物.

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...